Daily Respiratory Research Analysis
Analyzed 398 papers and selected 3 impactful papers.
Summary
Three impactful studies advance respiratory science this week: (1) a Nature Communications paper shows that small extracellular vesicles can transfer mitochondria to T-helper cells in human asthma, reprogramming their function; (2) a Redox Biology study identifies a SERPINE1–NAD+/Sirt3 axis that drives ferroptosis in ARDS, revealing a tractable therapeutic target; and (3) a multicenter SOFA-2 analysis improves sepsis identification and mortality prediction with external validation.
Research Themes
- Intercellular organelle transfer and immunometabolism in asthma
- Ferroptosis mechanisms and redox signaling in ARDS
- Sepsis scoring modernization and outcome prediction
Selected Articles
1. Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma.
Using human asthma samples and mechanistic assays, the authors show that small extracellular vesicles from myeloid-derived regulatory cells deliver mitochondrial cargo to CD4+ T-helper cells, reprogramming their bioenergetics and effector profiles. Mitochondrial transfer emerges as a key determinant of T-helper cell function, suggesting a therapeutic axis to modulate type 2 inflammation.
Impact: This study establishes intercellular mitochondrial transfer via sEVs as a mechanism shaping T-helper function in human asthma, providing a conceptual shift and tractable target for immunometabolic intervention.
Clinical Implications: Targeting sEV biogenesis, uptake, or mitochondrial cargo could modulate type 2 airway inflammation. EV-based or mitochondrial-targeted biomarkers may stratify patients and monitor response in severe asthma.
Key Findings
- Small extracellular vesicles from myeloid-derived regulatory cells transfer mitochondria to CD4+ T-helper cells.
- Mitochondrial transfer reprograms T-helper bioenergetics and alters effector cytokine profiles in human asthma.
- Interfering with sEV-mediated organelle transfer modulates T-helper function, revealing a therapeutic axis.
Methodological Strengths
- Use of human asthma samples with mechanistic validation of EV-mediated mitochondrial transfer
- Multimodal functional assays linking bioenergetics to T-helper effector programs
Limitations
- Primarily mechanistic/ex vivo data without interventional clinical trials
- Heterogeneity of EV sources and in vivo delivery not fully resolved
Future Directions: Define EV/mitochondrial cargo determinants of T-helper reprogramming in vivo, develop inhibitors or engineered EVs to modulate airway inflammation, and test biomarker-guided patient stratification in severe asthma trials.
Small extracellular vesicles (sEVs) orchestrate cell-cell communication, but the role of sEV signaling via mitochondria in perpetuating asthmatic airway inflammation is unknown. Myeloid-derived regulatory cells (MDRCs) control CD4
2. SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD
SERPINE1 is markedly upregulated in human ARDS, murine LPS-induced lung injury, and LPS-stimulated AT2 cells. Genetic or pharmacologic inhibition of SERPINE1 suppresses ferroptosis, restores epithelial protection (SLC7A11/GPX4/FTH1), and reduces lung injury. Mechanistically, SERPINE1 disrupts mitochondrial NAD+/NADH balance and Sirt3 activity (without direct Sirt3 binding) via interactions with complex I subunits and NNT, identifying a SERPINE1–NAD/Sirt3 axis as a driver of ferroptosis.
Impact: Reveals a previously unrecognized upstream pathway linking SERPINE1 to ferroptosis via mitochondrial redox control in ARDS, nominating SERPINE1 as a therapeutic target.
Clinical Implications: SERPINE1 inhibition or modulation of the mitochondrial NAD+/Sirt3 axis may attenuate epithelial ferroptosis and lung injury in ARDS; ferroptosis markers could inform patient stratification for redox-targeted therapies.
Key Findings
- SERPINE1 expression is elevated in ARDS patients, LPS-induced mouse lungs, and LPS-stimulated AT2 cells.
- SERPINE1 loss or pharmacologic inhibition suppresses ferroptosis and restores SLC7A11/GPX4/FTH1 expression, reducing lung injury.
- Mechanistically, SERPINE1 perturbs mitochondrial NAD+/NADH balance and Sirt3 activity via interactions with complex I subunits and NNT, without directly binding Sirt3.
Methodological Strengths
- Convergent evidence across human datasets, patient samples, mouse models, and AT2 cell systems
- Mechanistic dissection of mitochondrial redox signaling linking SERPINE1 to ferroptosis
Limitations
- Preclinical nature without interventional ARDS clinical trial data
- Pharmacologic tool specificity and in vivo dosing windows require further definition
Future Directions: Develop SERPINE1 inhibitors optimized for lung delivery, validate the SERPINE1–NAD/Sirt3 axis in human ARDS tissues longitudinally, and test ferroptosis-modulating therapies in biomarker-enriched trials.
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is characterized by alveolar epithelial injury, inflammatory dysregulation, oxidative stress, and impaired repair capacity. Ferroptosis, an iron-dependent and lipid peroxidation-driven form of regulated cell death, has emerged as a pathogenic driver of ARDS; however, the upstream molecular regulators that initiate ferroptotic signaling in alveolar epithelial cells remain poorly defined. SERPINE1 (PAI-1), a mediator of inflammation, coagulation dysfunction, and epithelial injury, is frequently elevated in sepsis and ARDS, yet its mechanistic role in ferroptosis remains unknown. METHODS: Transcriptomic analysis of ARDS datasets, LPS-induced mouse models, clinical serum samples, and LPS-stimulated AT2 cells were used to assess SERPINE1 expression. Gain- and loss-of-function approaches, ferroptosis assays, mitochondrial functional analyses, NAD
3. The new SOFA for sepsis identification and mortality prediction: a multicenter cohort study.
Across 11,669 ICU admissions with external validation in 29,811 patients, SOFA-2 identified more sepsis cases (49.0% vs 45.5%) than SOFA-1 with substantial agreement and modestly improved mortality discrimination. The Sepsis-3 threshold (SOFA ≥2) appears appropriate with SOFA-2, supporting clinical adoption.
Impact: Provides multicenter, externally validated evidence that a modernized SOFA implementation modestly enhances sepsis detection and prognostication without changing Sepsis-3 thresholds.
Clinical Implications: ICUs can adopt SOFA-2 for sepsis surveillance and risk stratification with confidence that Sepsis-3 operational thresholds remain applicable; this may standardize practice and modestly improve early identification.
Key Findings
- In 11,669 ICU admissions, SOFA-2 identified more sepsis cases than SOFA-1 (49.0% vs 45.5%).
- External validation in 29,811 ICU patients confirmed substantial diagnostic agreement and modestly better mortality discrimination with SOFA-2.
- Sepsis-3 threshold (SOFA ≥2) does not require recalibration when applying SOFA-2.
Methodological Strengths
- Large multicenter cohort with external validation in an independent large ICU dataset
- Direct comparison of diagnostic yield and prognostic discrimination with contemporary organ support practices
Limitations
- Retrospective design reliant on EHR data quality and coding
- Clinical impact (workflow and outcomes) of adopting SOFA-2 not prospectively tested
Future Directions: Prospective implementation studies to quantify workflow impact and patient outcomes with SOFA-2–guided sepsis pathways; evaluation across diverse health systems.
BACKGROUND: The Sequential Organ Failure Assessment (SOFA) score is central to Sepsis-3 criteria. SOFA-2 updates thresholds and incorporates contemporary organ support practices, but its impact on sepsis identification and outcome prediction remains uncertain. This study aimed to compare the diagnostic yield and prognostic performance of SOFA-2 versus SOFA-1 for sepsis identification in critically ill adults. METHODS: We conducted a retrospective multicenter cohort study of 11,669 ICU admissions from three tertiary hospitals in China (January 2022-October 2025) and externally validated findings in 29,811 ICU patients from MIMIC-IV. Sepsis was defined by Sepsis-3 using either SOFA-1 or SOFA-2. We evaluated diagnostic agreement, organ dysfunction profiles, and discrimination for ICU mortality. RESULTS: SOFA-2 identified a significantly larger sepsis population than SOFA-1 (49.0% vs. 45.5%, P < 0.001), while maintaining substantial diagnostic agreement with SOFA-1 ( CONCLUSION: The updated SOFA-2 score may identify a moderately larger sepsis population with more advanced organ dysfunction and may provide modestly improved mortality risk stratification compared with SOFA-1, while maintaining substantial diagnostic agreement. These findings suggest that SOFA-2 could be considered for clinical use in ICU sepsis assessment, and the Sepsis-3 SOFA ≥ 2 threshold may not require recalibration when using SOFA-2.